Key facts
- GrayMatters Health’s last known valuation is $32.8M (Apr 2024).
- It has raised $19.0M; the latest was Later Stage VC ($1.1M) in Oct 2025.
- Notable investors include European Innovation Council, Endless Frontier Labs, Joyance Partners, Marius Nacht, 28DIGITAL — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for GrayMatters Health
- ·The full record, as it builds
Funding rounds
No funding rounds for GrayMatters Health are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About GrayMatters Health
Developer of a health technology designed to develop a self-neuromodulation treatment based on brain biomarkers associated with mental health disorders. The company's digital therapeutics follow the self-regulation of brain processes to solve the issues related to mental health and neurologic disorders and mental healthcare professionals with a neuroscience-based technology that bridges the gaps of efficacy, safety, and accessibility for healthcare common procedure coding system and patients, enabling patients suffering from neurological disorders to treat their diseases in a hassle-free manner.
- Sector
- Healthcare
- HQ
- Haifa, Israel
- Founded
- 2018
- Employees
- 32
- Website
- graymatters-health.com/
- Ownership
- Privately Held (backing)
GrayMatters Health doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GrayMatters Health shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GrayMatters Health in its N-PORT filings yet. We sweep new filings monthly.